Long-term physiologic T3 supplementation in hypertensive heart disease in rats

Animal studies suggest that hypertension leads to cardiac tissue hypothyroidism, a condition that can by itself lead to heart failure. We have previously shown that short-term thyroid hormone treatment in Spontaneously Hypertensive Heart Failure (SHHF) rats near heart failure is beneficial. This study tested the hypothesis that therapeutic, long-term T3 treatment in SHHF rats can prevent or attenuate cardiac dysfunction. Female SHHF rats were treated orally with a physiological T3 dose (0.04μg/ml) from 12-24 months of age. Age matched female SHHF and Wistar Kyoto rats served as hypertensive and normotensive controls, respectively. SHHF rats had reduced serum free thyroid hormone levels and cardiac tissue T3 levels, LV dysfunction and elevated LV collagen content compared to normotensive controls. Restoration of serum and cardiac tissue thyroid hormone levels in T3 treated rats was associated with no change in heart rate, but strong trends for improvement in LV systolic function and collagen levels. For instance, end-systolic diameter, fractional shortening, systolic wall stress, and LV collagen levels were no longer significantly different from controls. In conclusion, longstanding hypertension in rats led to chronic low serum and cardiac tissue thyroid hormone levels. Long-term treatment with low dose T3 was safe. While cardiac dysfunction could not be completely prevented without treatment of hypertension, T3 may offer additional benefits as an adjunct therapy with possible improvement in diastolic function.